| [Interaction of a synthetic fragment of the oncoprotein p21ras with cellular proteins]. | None |
| this study uncovers a mechanism by which oncogenic RAS preserves intracellular redox balance and identifies an unexpected role for xCT in supporting RAS-induced transformation and tumorigenicity. | None |
| Characterization of c-Ki-ras oncogene alleles by direct sequencing of enzymatically amplified DNA from carcinogen-induced tumors. | None |
| Studies suggest that carcinoembryonic antigen and cytology are more accurate than KRAS proto-oncogene [Review and Meta-Analysis]. | None |
| study highlights a context-dependent contribution of SHOC2 to ERK pathway dynamics that is preferentially engaged by KRAS oncogenic signaling | None |
| Oncogenic KRAS, together with beta-Catenin, favours expansion of crypt cells with high ERK activity. | None |
| Selective Killing of RAS-Malignant Tissues by Exploiting Oncogene-Induced DNA Damage. | None |
| Affinity labeling of ras oncogene product p21 with guanosine diphospho- and triphosphopyridoxals. | None |
| Oncogene ras p21- and v-src pp60-transformed cells exhibit altered expression of proteases. | None |
| KRAS2 oncogene overexpression in myelodysplastic syndrome with translocation 5;12. | None |
| Early cellular responses to the activation of a mitogenic/oncogenic viral K-RAS protein. | None |
| In situ localization of murine c-Ki-ras-2 oncogene: preliminary evidence for conservation of telomeric territory of oncogenes?. | None |
| Amplification of c-Ki-ras-2 oncogene sequences in human carcinoma of pancreas. | None |
| Antibodies against synthetic carboxy-terminal peptides distinguish H-ras and K-ras oncogene products p21. | None |
| [Immunoassays of cancer markers--production and analysis of monoclonal antibodies reactive with ras oncogene p21]. | None |
| Interaction of ras oncogene product p21 with guanine nucleotides. | None |
| Two adjacent mutations at position 12 activate the K-ras2 oncogene of a human mammary tumor cell line. | None |
| Detection of genes with potential of suppressing transforming activity of the v-Ki-ras oncogene. | None |
| The oncogenic activation of human p21ras by a novel mechanism. | None |
| Development of quantitative liquid competition radioimmunoassays for the ras oncogene and proto-oncogene p21 products. | None |